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BACKGROUND: Cellular proliferation, driven by cyclin-dependent kinases (CDKs) and their cyclin partners, is deregulated in cancer.
Anti-estrogens, such as tamoxifen, antagonise estrogen-induced ERa transactivation of cyclin D1, resulting in reduced CDK4/6 activity,
p27
Kip1-mediated inhibition of CDK2 and growth arrest. We hypothesised that direct inhibition of CDK2 and CDK1 may overcome
the major clinical problem of anti-estrogen resistance.
METHODS: The cellular effects of CDK2/1 siRNA knockdown and purine-based CDK2/1 inhibitors, NU2058 and NU6102, were
measured in anti-estrogen-sensitive and resistant breast cancer cell lines.
RESULTS: CDK2 knockdown caused G1 accumulation, whereas CDK1 depletion caused G2/M slowing, and dual CDK1/2 depletion
resulted in further G2/M accumulation and cell death in both anti-estrogen-sensitive and resistant cells, confirming CDK2 and CDK1
as targets for breast cancer therapy. In contrast to tamoxifen, which only affected hormone-sensitive cells, NU2058 and NU6102
reduced CDK2-mediated phosphorylation of pRb, E2F transcriptional activity and proliferation, ultimately resulting in cell death, in
both anti-estrogen-sensitive and resistant cells. Both drugs caused G2/M arrest, reflective of combined CDK2/1 knockdown, with a
variable degree of G1 accumulation.
CONCLUSION: These studies confirm the therapeutic potential of CDK2 and CDK1 inhibitors for cancer therapy, and support their use
as an alternative treatment for endocrine-resistant breast cancer.
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Anti-estrogens, including tamoxifen, are the mainstay of treatment
for hormone-dependent breast cancers. However, intrinsic and
acquired anti-estrogen resistance is a significant clinical problem
(Ali and Coombes, 2002). Tamoxifen competitively blocks
estrogen–estrogen receptor a (ERa) binding and reduces ERa-
mediated transcription of cell cycle genes. The mammalian cell
cycle is regulated by the periodic association of cyclin-dependent
kinases (CDKs) with their cyclin partners and kinase inhibitor
proteins (for example, p21
Waf1/Cip1 and p27
Kip1). The G1/S transition is
promoted by sequential CDK4/6/cyclin D1-mediated and CDK2/cyclin
E-mediated phosphorylation of the retinoblastoma protein (pRb).
Phosphorylation of pRb relieves transcriptional repression by the
pRb–E2F complex and disrupts the binding of pRb to E2F, allowing
E2F activation and transcription of genes necessary for S-phase
entry and progression. In anti-estrogen-responsive breast cancers,
tamoxifen causes a reduction in cyclin D1 expression, reducing
CDK4/6 activity and promoting p27
Kip1/p21
Waf1/Cip1 inhibition of
CDK2, resulting in decreased pRb phosphorylation and G1 cell cycle
arrest (Planas-Silva and Weinberg, 1997).
Estrogen-independent and more aggressive breast cancers tend
to have low p27
Kip1 levels, which is an independent indicator of
poor prognosis (Chiarle et al, 2001). Transfection of p27
Kip1 into
human mammary tumour cells caused a decrease in cyclin E/CDK2
activity, G1 accumulation and suppression of in vivo tumouri-
genicity (Carroll et al, 2003). Ectopic expression of p27
Kip1 and
p21
Waf1/Cip1 may also inhibit CDK1, which has a critical role at
the G2/M boundary, and has recently been implicated in G1/S
control (Satyanarayana et al, 2008). Therefore, the direct targeting
of CDK2 and CDK1 may be a useful therapeutic approach,
particularly in anti-estrogen-resistant breast cancers (AERBC),
where p27
Kip1 levels are reduced.
Studies in breast cancer have highlighted CDK2 as an essential
regulator of estrogen-mediated G1/S transition (Planas-Silva and
Weinberg, 1997; Cariou et al, 2000); however, recent studies in
non-breast cancer cell lines and in knockout mice have questioned
the role of CDK2 in cancer cell proliferation (Berthet et al, 2003;
Ortega et al, 2003; Tetsu and McCormick, 2003). To date, the
effects of CDK2 knockdown in breast cancer cell lines have not
been determined. Here, we examined the consequences of siRNA-
mediated CDK2 knockdown in a range of anti-estrogen-sensitive
and resistant breast cancer cells. Because reduced CDK2 activity
can be compensated by CDK1 (Cai et al, 2006), we also examined
the effects of CDK1 and combined CDK2/CDK1 depletion. The
effects of the dual CDK2 and CDK1 inhibitors NU2058 (Arris et al,
2000) and NU6102 (Davies et al, 2002) were also compared with
combined CDK2 and CDK1 knockdown. As a model of anti-
estrogen resistance in the clinical setting, we used a parental MCF7
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scell line and compared it with two MCF7-derived cell sublines,
LCC9 and MMU2, generated by selecting for growth in the
presence of anti-estrogens (Brunner et al, 1997; Limer et al, 2006).
In addition, the effects of CDK1/2 knockdown and inhibition were
measured in T47D (tamoxifen sensitive), MDA-MB-231 and
HCC1937 (tamoxifen resistant) cell lines. Overall, the results
reported in the present study provide the first evidence for the
potential use of CDK2/1-specific inhibitors in AERBC.
MATERIALS AND METHODS
Materials
Radiolabelled g[
32P]ATP (specific activity¼0.37MBqml
 1 ) was
obtained from Amersham Biosciences (Buckinghamshire, UK).
NU2058 and NU6102 were provided by Professor RJ Griffin
(Northern Institute for Cancer Research, Newcastle University,
Newcastle, UK), dissolved in DMSO at 100mM and stored at
 201C. Tamoxifen (Sigma, Poole, UK) was dissolved in DMSO at
10mM and stored at  201C. Flavopiridol was provided by the Drug
Synthesis and Chemistry Branch, Developmental Therapeutics
Program, Division of Cancer Treatment and Diagnosis, National
Cancer Institute (Bethesda, MD, USA). A 50mmoll
 1 stock
solution in DMSO was maintained at  201C. All other chemicals
and reagents were from Sigma unless stated otherwise. Drugs were
added to cells in a final DMSO concentration of 0.1%.
Cell culture
MCF7, T47D, MDA-MB-231, HCC1937 cells, obtained from the
American Tissue Culture Collection (Manassas, VA, USA) were
grown in RPMI 1640 medium supplemented with 10% (v/v) fetal
bovine serum, penicillin (50Uml
 1) and streptomycin
(50mgml
 1) unless otherwise stated. MMU2 cells, a tamoxifen-
resistant MCF7 derivative generated by selection for growth in
the presence of tamoxifen (Limer et al, 2006), were a gift from
Dr Valerie Spiers (University of Leeds, Leeds, UK). LCC9 cells,
an anti-estrogen-resistant derivative of MCF7 cells selected for
growth in the presence of the anti-estrogen ICI 182,780 and cross-
resistant to tamoxifen (Brunner et al, 1997), were a gift from
Robert Clarke (Georgetown University School of Medicine,
Georgetown, USA). MMU2 cells were grown in phenol red-free
RPMI 1640 medium and LCC9 cells in phenol red-free Dulbecco’s
minimum essential medium (Gibco–Invitrogen, Paisley, UK),
supplemented with dextran charcoal-stripped 10% (v/v) FCS and
penicillin (50Uml
 1) and streptomycin (50mgml
 1). Before the
experiment, MMU2 cells underwent two passages in full RPMI
1640 medium and LCC9 cells underwent two passages in full
minimum essential medium (Gibco–Invitrogen). All cells were
grown in fully supplemented media during the experimental
procedures.
Growth inhibition and colony assays
To measure growth inhibition, cells were exposed to varying
concentrations of tamoxifen, NU2058 and NU6102, or 0.1% (v/v)
DMSO, as control, for 6 days (three cell doublings) or 7 days for
HCC1937 (three cell doublings), then fixed and stained with
sulforhodamine B, as described previously (Skehan et al, 1990). To
measure cell survival after 24-h drug exposure or at 72h after
siRNA treatment, 1000 or 5000 cells were seeded in 10-cm dishes.
At 2 weeks after plating, cells were fixed with 3:1 methanol–acetic
acid and stained with 0.4% crystal violet to assess colony
formation. The concentration required to inhibit cell growth by
50% (GI50) or reduce colony formation by 50% (LC50), was
calculated from point-to-point graphs using GraphPad Prism
(San Diego, CA, USA) software.
Cell cycle analysis and western blotting
Cell cycle analyses and western blotting were carried out as described
previously (Cai et al, 2006). Treatments are described in individual
figure legends, and for western blotting, cells were probed with primary
antibodies cyclin D1, p27
Kip1,p 2 1
Waf1/Cip1 (Cell Signaling, Baltimore,
M A ,U S A ) ;t o t a lp R b( B DP h a r m i n g e n ,S a nD i e g o ,C A ,U S A ) ;p p R b
T821 (Biosource, Bethesda, MD, USA); ppRb S807/811 (New England
Biolabs, Beverly, MA, USA); Cyclin D1, p53, ERa (Dako, Carpinteria,
CA, USA); actin (Sigma); CDK4, CDK2, CDK1, Cyclin A, Cyclin E, total
RNA polymerase II (Santa Cruz, Santa Cruz, CA, USA); RNA
polymerase II [pSer
2] (Abcam, Cambridge, MA, USA); RNA
polymerase II [pSer
5] (Covance, San Diego, CA, USA)). Blots were
incubated with peroxidase-conjugated swine anti-rabbit or mouse
secondary antibody (Dako). Chemiluminescence was detected using a
dark box with a CCD camera (Fuji LAS 3000, Raytek, UK) and
quantified using Aida image analyser software (Raytek, UK).
E2F luciferase reporter gene assay
Cells were transfected with the E2F reporter construct (200ng)
(Hofman et al, 2001) together with the b-galactosidase construct
(200ng) (Brady et al, 1999) using FuGENE6 transfection reagent
(Roche Diagnostics, Lewes, UK) and treated as indicated in figure
legends. Luciferase activity was determined after addition of 50ml
luciferase reagent (Promega, Southampton, UK) using a microplate
luminometer (Perkin-Elmer, Beaconsfield, UK). To monitor the
transfection efficiency, lysates were assayed for b-galactosidase
activity by addition of b-galactosidase reagent and incubated at
371C for 45min before terminating the reaction with 1 M Na2CO3.
Absorbance at 450nm was read on a microtitre plate reader
(Bio-Rad, Hemmel Hempstead, UK). Luciferase activity was
normalised to the b-galactosidase activity and expressed as a
percentage of the DMSO control.
siRNA-mediated CDK knockdown
Cells were seeded in six-well plates and allowed to adhere for
24h. siRNA double-stranded, annealed RNA oligonucleotides,
Smart pool siRNA from Dharmacon (Chicago, USA) (CDK1, no.
L-003224-00; CDK2, no. L-003236-00), were diluted in full media to
a final concentration of 20nM and mixed with RNAifect trans-
fection reagent (Qiagen, Cambridge, UK), then added at 7mlml
 1
in RPMI to the cells for 12h before replacing with fresh medium.
CDK immunoprecipitation and kinase assays
Cyclin-dependent kinase immunoprecipitation and cdk kinase
assays were carried out as described previously (Cai et al, 2006).
X-ray films were analysed and quantified using a CCD camera
(Fuji LAS 3000) and Aida image analyser software.
Statistical analysis
Statistically significant changes were determined by unpaired
Student’s t-test using GraphPad Prism software. Statistical
significance is given by *Pp0.05, **Pp0.01, ***Pp0.001.
RESULTS
Individual and combined CDK2 and CDK1 depletion
results in cell cycle arrest in anti-estrogen-sensitive and
resistant breast cancer cell lines
First, we confirmed the anti-estrogen sensitivity status of a panel of
breast cancer cell lines. MCF7 and T47D cell lines were considered
tamoxifen sensitive (GI50p3mM), whereas MMU2, LCC9, MDA-MB-
231 and HCC1937 were tamoxifen resistant (GI5043mM)( F i g u r e1 ) .
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sTo evaluate the importance of CDK2 and CDK1 in breast cancer
cell growth and their validity as a drug targets in breast cancer,
CDK2 and CDK1 protein levels were transiently knocked down
with siRNA treatment, either individually or in combination, in the
exponentially growing breast cancer cell lines. All cell lines showed
substantial knockdown of CDK2 and CDK1 (Figure 2A). Cyclin-
dependent kinase-2 knockdown caused significant G1 accumula-
tion in MCF7 (1.4-fold**) and LCC9 (1.3-fold**) cell lines, with
only marginal increase in T47D (1.1-fold) and HCC1937 (1.2-fold)
cell lines. There were corresponding significant reductions in
S-phase fractions in MCF7 (1.5-fold**), LCC9 (1.6-fold***), T47D
(1.4-fold**) and HCC1937 (1.6-fold**) cell lines. Cyclin-dependent
kinase-2 knockdown did not affect the cell cycle pattern of MMU2
and MDA-MB-231 cell lines. Cyclin-dependent kinase-1 knock-
down caused very significant G2/M accumulation in all cell lines –
MCF7 (2.6-fold***), MMU2 (1.3-fold**), LCC9 (2-fold***), T47D
(1.6-fold**), MDA-MB-231 (2-fold**) and HCC1937 (2.3-fold***) –
with co-depletion of both CDK2 and CDK1 together, causing
the greatest increases in G2/M cell cycle fractions of MCF7
(4.8-fold***), MMU2 (1.6-fold***), LCC9 (2.8-fold***), T47D
(2.8-fold***), MDA-MB-231 (3.3-fold***) and HCC1937 (2.9-
fold***) cell lines (Figure 2B).
Cyclin-dependent kinase-2 depletion also reduced colony form-
ation to varying degrees in all cell lines (MCF7-23%, MMU2-15%,
LCC9-9%, T47D-5% MDA-MB-231-6% and HCC1937-63% reduc-
tion in colony formation). Cyclin-dependent kinase-1 depletion
further reduced colony formation to a similar degree in all cell
lines (440% reduction). Combined CDK2 and CDK1 depletion
vastly diminished the number of colony-forming cells in all cell
lines (490% reduction) (Figure 2C).
CDK1/2 inhibition reduced cell proliferation and colony
formation irrespective of anti-estrogen sensitivity status
Combined CDK1/2 depletion caused cell cycle arrest and cell death
in both anti-estrogen-sensitive and resistant breast cancer cell lines
tested. We therefore set out to investigate whether this could be
mimicked using small-molecule CDK1/2 inhibitors, NU2058 and
NU6102 (Supplementary Table 1 and Supplementary Figure 1). In
contrast to tamoxifen, NU2058 was almost equally potent against
all breast cancer cell lines irrespective of their anti-estrogen status,
with GI50 values ranging between 29 and 42mM. NU6102 was a
more potent inhibitor of cell growth, with GI50 values of 5–18mM
across the panel (Supplementary Figure 2A, B and Figure 3A).
Furthermore, NU2058 reduced colony formation, indicative of cell
death, with LC50 values ranging between 78 and 94mM. Similarly,
NU6102 reduced cell survival, with LC50 values ranging between 6
and 14mM (Supplementary Figure 2C, D and Figure 3B).
We next went on to measure the effects of tamoxifen, NU2058
and NU6102 on cyclin D1, p21
Waf1/Cip1, p27
Kip1 and pRb
phosphorylation at T821 – a preferential CDK2-mediated phos-
phorylation site (Zarkowska and Mittnacht, 1997). For these
studies, we focused on the parental anti-estrogen-sensitive MCF7
cell line and its anti-estrogen-resistant derivatives, MMU2 and
LCC9 cells, because (a) their common origin provided a more
similar genotype/phenotype for the characterisation of CDK
inhibitors and (b) their derivation mimicked the acquisition of
anti-estrogen resistance clinically (Figure 4A).
Exposure of asynchronous cells for 24h to tamoxifen at 2mM
(BGI50 in MCF7 cells) and 8mM (BGI50 in MMU2 and LCC9 cells)
(Figure 1) (Johnson et al, 2008) reduced cyclin D1 and increased
p21
Waf1/Cip1 and p27
Kip1 levels; consequently, CDK2 activity was
diminished, reflected by decreased pRb
pThr821 protein levels in parental
MCF7 cells. Tamoxifen had little or no effect on protein levels
measured in MMU2 and LCC9 cells. There was also little or no change
in cyclin D1, p21
Waf1/Cip1 and p27
Kip1 levels in all cell lines treated with
NU2058 or NU6102. In contrast, 25mM (BGI50 concentration) and
75mM NU2058 (BGI90 concentration) reduced pRb
pThr821 levels to a
similar extent in all cells. Exposure to 5mM NU6102 reduced the levels
of pRb
pThr821 in the more sensitive LCC9 cell line (GI50B5mM); 15mM
NU6102 was required to detect reduced pRb
Thr821 phosphorylation in
MCF7 (GI50B15mM) and MMU2 (GI50B10mM) cells (Figure 4A).
Downstream of pRb phosphorylation, E2F transcriptional activity was
reduced by tamoxifen (2mM) to a greater extent in MCF7 cells than in
the hormone-resistant cells, whereas NU2058 (75mM) and NU6102
(15mM) caused similar reductions in all of the cell lines (Figure 4B).
The changes in the levels of phosphorylated pRb and E2F activity
were reflected in changes in cell cycle distribution (Figure 4C). In
MCF7 cells, tamoxifen caused a concentration-dependent increase in
G1 (2mM, 1.27-fold* and 8mM, 1.57-fold***) and reduction in S-phase
(2mM, 1.17-fold and 8mM, 1.87-fold**) fractions. However, in MMU2
and LCC9 cells, even at 8mM tamoxifen only caused a marginal
increase in G1 accumulation (MMU2, 1.1-fold; LCC9, 1.19-fold) and
S-phase depletion (MMU2 (8mM), 1.23-fold, LCC9, 1.37-fold*).
Treatment with 25mM NU2058 caused significant G1 accumu-
lation in MCF7 (1.48-fold*) and LCC9 (1.21-fold*) cell lines and a
corresponding decrease in S-phase fraction in MCF7 (2.2-fold*)
and LCC9 (1.32-fold*) cell lines, but no significant change in
MMU2 cells. Exposure to 75mM NU2058 caused a further G1
accumulation in LCC9 cell lines (1.36-fold***) and G2 accumula-
tion in MCF7 (1.63-fold*) and MMU2 (1.6-fold*) cell lines.
However, there was a significant S-phase depletion in all cells –
MCF7 (3.44-fold***), MMU2 (2.66-fold*) and LCC9 (3.57-fold**).
Treatment of asynchronous populations with 5mM NU6102
arrested cells at the G2/M boundary with an increase in G2/M
fraction in MCF7 (2.33-fold*), MMU2 (1.95-fold**) and LCC9
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Figure 1 Effect of tamoxifen on breast cancer cell lines growth. (A) Inhibition of breast cancer cell growth by tamoxifen after 6 days. Data are mean and
s.e. of three independent experiments. Left – graphs showing MCF7, MMU2 and LCC9 cell growth inhibition. Right – graphs showing MCF7, T47D, MDA-
MB-231 and HCC1937 cell growth inhibition. (B) Tamoxifen concentrations required to inhibit breast cancer cell growth by 50% of that of vehicle-treated
control over a 6-day period. Bars show mean and s.e. of concentrations from three independent experiments.
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s(3.4-fold**) cell lines compared with the DMSO control. There was
little further cell cycle perturbation caused by increasing the
NU6102 concentration to 15mM (Figure 4C).
NU2058 and NU6102 reduce pRb phopshorylation and
prevent G1 exit after release from serum deprivation
We investigated the effects of tamoxifen, NU2058 and NU6102 on
the ability of cells to transit through G1 into S-phase. We first
measured pRb phosphorylation at 8 and 24h after release from
serum starvation-induced G0/1 arrest (Figure 5A). In parental
MCF7 cells, at 8h after serum addition, pRb
pSer807/811 levels,
indicative of CDK4/6 activity (Driscoll et al, 1999), had substan-
tially increased, and by 24h, pRb
pSer807/811 and pRb
pThr821 levels
had fully recovered. Tamoxifen caused a significant decrease in
pRb phosphorylation at both time points in MCF7 cells. Tamoxifen
did not alter pRb phosphorylation in MMU2 or LCC9 cells at either
time points. In contrast, both NU2058 and NU6102 caused
concentration-dependent reductions in pRb phosphorylation after
serum release in all three cell lines.
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CDK2 (K1/2) siRNA in asynchronously growing breast cancer cells. (B) Cell cycle analysis data pooled from three independent experiments expressed as
the mean G1 (solid bar), S (open bar) and G2/M (grey bar) cell cycle fractions of cells treated as given in A.( C) Mean and s.e. of colony formation for cells
treated as given in A; colony formation was assessed at 2 weeks post-transfection.
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re-entry in MCF7 cells, resulting in a significant concentration-
dependent increase in the G1 population (2mM, 1.95** and 8mM,
2.7-fold**) and reduction in S-phase fractions (2mM, 1.2* and 8mM,
1.75-fold*) compared with the DMSO control. However, in MMU2
and LCC9 cells, tamoxifen caused only a modest retention in G1
and inhibition of progression into S-phase, which was not
significant.
NU2058 had little effect at 25mM on preventing G1 exit after
release from serum starvation in any of the cell lines. However,
75mM NU2058 prevented G1 exit in all cell lines, resulting in a
significantly increased G1 fraction in MCF7 (2.74-fold**), MMU2
(1.58-fold*) and LCC9 (1.73-fold**) cell lines compared with
DMSO control and reduced S-phase entry in MCF7 (2.54-fold*),
MMU2 (3.5-fold*) and LCC9 (3.8-fold*) cell lines compared with
DMSO control.
The addition of 5mM NU6102 to synchronous cultures had little
effect on MCF7 cell cycle distribution. However, it caused an
increase in G2/M cell cycle fractions in MMU2 (2.85-fold*) and
LCC9 cells (1.86-fold*), with a corresponding decrease in the
S-phase populations in MMU2 (2.65-fold***) and LCC9 (1.52-
fold**) cell lines. In contrast to asynchronously growing cultures,
15mM NU6102 arrested synchronised cell populations in the
G1-phase in all cells – MCF7 (3.34-fold**), MMU2 (1.26-fold)
and LCC9 1.45-fold*) – compared with DMSO control and
decreased the S-phase fractions in MCF7 (3.5-fold*), MMU2
(1.83-fold*) and LCC9 (2.9-fold*) cell lines compared with DMSO
control (Figure 5B).
NU2058 and NU6102 are equipotent CDK2 and CDK1
inhibitors in intact cells
Inhibition of human CDK2 and starfish CDK1 by NU2058 and
NU6102 has previously been described (Arris et al, 2000; Davies
et al, 2002; Hardcastle et al, 2002). Subsequent evaluation of these
inhibitors against human CDK1 showed that NU6102 is 50-fold
more active against CDK2/cyclin E than CDK1/cyclin B (IC50¼5
and 250nM), and that NU2058 has 1.5-fold selectivity for CDK2/
cyclin E (IC50¼17mM) over CDK1/cyclin B (IC50¼26mM) (L-Z
Wang, unpublished data). However, treatment of exponentially
growing cells with NU2058 or NU6102 resulted in G2/M arrest,
which is typical of combined CDK2 and CDK1 inhibition.
We therefore investigated CDK2 and CDK1 inhibition by
NU2058 and NU6102 in whole cells by immunoprecipitating
CDK2 and CDK1 from intact MCF7 cells, which had been treated
with inhibitors for 1h, and measuring their ability to phos-
phorylate Histone H1. The concentrations required to inhibit
CDK2 by 50% were estimated as 54mM for NU2058 and 9mM for
NU6102 by quantitative densitometry (Figure 6A). Strikingly,
similar concentrations were required to inhibit CDK1 by 50%, that
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sis, 65mM for NU2058 and 11mM for NU6102 (Figure 6B). Therefore,
despite their selectivity for CDK2 in enzymatic assays, in MCF7
cells, both compounds were equipotent against cellular CDK2 and
CDK1. Importantly, cell growth inhibition by NU2058 and NU6102
(Figure 3) was observed at concentrations that inhibited CDK2 and
CDK1 in intact cells.
To determine the effects of these compounds on the activity of
the transcriptional CDKs, we measured p53 accumulation and
levels of RNA polymerase II phosphorylation. Neither NU2058 (25
and 75mM) nor NU6102 (5 and 15mM) affected phospho-serine 2 or
5-RNA polymerase II or p53 levels, indicating that they were not
inhibiting the activity of transcriptional CDKs in cells (Figure 6C).
In contrast, flavopiridol, a potent CDK9 inhibitor, did reduce RNA
polymerase II phosphorylation and increased p53 levels. Further-
more, when CDK1/2-depleted cells were treated with NU2058 and
NU6102 and cell survival was measured, there was no further
reduction in colony formation compared with CDK1/2 knockdown
alone. This provides additional evidence that inhibition of CDK1
and CDK2 is the mechanism by which NU2058 and NU6102 kill
breast cancer cells (Figure 6D).
DISCUSSION
The development of resistance to hormonal therapies is a major
problem in the treatment of breast cancer. Because anti-estrogen
therapy results in a reduction in cyclin D1 levels and p21
Waf1/Cip1/
p27
Kip1-mediated inhibition of CDK2/1 activity, we sought to
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Figure 4 Cell cycle effects of tamoxifen, NU2058 or NU6102 on asynchronously growing MCF7 cell lines. (A) Representative western blot of cyclin D1,
p21
Waf1/Cip1, p27
Kip1, ppRb T821 and total pRb protein levels in asynchronously growing MCF7, MMU2 and LCC9 cells exposed to 2 or 8mM tamoxifen,
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luciferase reporter construct and a b-gal reporter plasmid. Relative luciferase activity was then expressed as a percentage of the DMSO-treated control. Data
are mean±s.e. of three independent experiments. (C) Flow cytometric analyses of cells treated with tamoxifen and cyclin-dependent kinases-1/2 (CDK2/1)
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sdetermine the ability of novel guanine-based CDK2/1 inhibitors
NU2058 and NU6102 to target CDK2 and CDK1, and assess
their therapeutic potential as alternatives to hormonal therapy
in breast cancer. Cyclin-dependent kinase-2 and CDK1 were
validated as therapeutic targets using transient siRNA knockdown.
Studies in other cancer cell lines measuring cell cycle effects of
individual CDK2 depletion showed little change in cell cycle
profiles of asynchronous cells due to compensation by other CDK
family members, including CDK1 and CDK4/6 (Cai et al, 2006).
However, our data show that, in breast cancer cells, CDK2
depletion resulted in G1 accumulation, and a reduction in the
S-phase fractions in both tamoxifen-sensitive MCF7 and T47D
cells, and resistant LCC9 and HCC1937 cells, indicating that
CDK2 knockdown or inhibition may not be as easily compensated
in all cell types, and may have an important role in G1 progres-
sion in breast cancer cells compared with other types of cancer
cells. Furthermore, CDK2 depletion resulted in partial cell death in
these cell lines; in particular, CDK2 depletion caused a large
reduction in colony formation in the anti-estrogen-resistant
BRCA1-mutant HCC1937 cells. BRCA1-depleted breast cancer
cells have previously been shown to be sensitive to CDK2 depletion
or inhibition (Deans et al, 2006). Moreover, MCF7 cells which
developed anti-estrogen resistance through loss of pRb expression,
had increased cyclin A expression and CDK2 activation, and were
still highly dependent on CDK2, but not on CDK4 activity
for proliferation (Varma et al, 2007). These studies suggest that
CDK2 inhibition may be of therapeutic value for several subgroups
of AERBC.
Cyclin-dependent kinase-1 depletion reduced colony formation
to a greater extent than did CDK2 depletion, probably because of
the inability of CDK2 to fully compensate for CDK1 loss (Johnson
et al, 2009). Combined CDK1 and CDK2 depletion caused massive
reduction in colony formation in all cell lines, suggesting that
small-molecule inhibition of CDK1 and CDK2 may be an effective
strategy for treatment of both anti-estrogen-sensitive and resistant
breast cancer populations.
After establishing that combined CDK2 and CDK1 depletion
caused cell cycle arrest and cell death in both anti-estrogen-
sensitive and resistant breast cancer cells, we investigated whether
similar effects could be achieved by reducing CDK activity with
MCF7 AB MCF7
C
e
l
l
s
 
%
100
80
60
40
20
0
C
e
l
l
s
 
%
100
80
60
40
20
0
C
e
l
l
s
 
%
100
80
60
40
20
0
MMU2
MMU2
LCC9
LCC9
8 h
0282 5 7 55 15 0282 5 7 55 (M) 15
028 2 5 7 5 5 1 5
+
pRb[T821]
pRb[S807/811]
Rb
Actin
pRb[T821]
pRb[S807/811]
Rb
Actin
pRb[T821]
pRb[S807/811]
Rb
Actin
–
+–
Tam NU2058 NU6102
Tam NU2058 NU6102
0 2 82 5 7 55 15 +–
Tam NU2058 NU6102
0282 5 7 55 15 +–
Tam NU2058 NU6102
Tam NU2058 NU6102
24 h
8 h
0 2 8 25 75 5 15 0 2 8 25 75 5 15 +–
Tam NU2058 NU6102 Tam NU2058 NU6102
24 h
8 h
0282 5 7 5 5 15 02 82 57 55 15 +–
Tam NU2058 NU6102 Tam NU2058 NU6102
24 h
(M)
(M)
(M)
(M)
(M)
Figure 5 Effect of tamoxifen, NU2058 or NU6102 on phosphorylated pRb levels and cell cycle distribution in synchronously growing MCF7 cell lines. (A)
Phosphorylated and total pRb in lysates of exponentially growing cells (þ), cells serum starved for 24h ( ) or serum starved for 24h and released into full
medium in the presence of 0.1% (v/v) DMSO, 2 or 8mM tamoxifen, 25 or 75mM NU2058, 5 or 15mM NU6102 for 8 and 24h after release. (B) Flow
cytometric analysis of cells treated as described in A and harvested at 24h after serum release, expressed as the mean G1 (solid bar), S (open bar), G2/M
(grey bar) cell cycle fractions from three independent experiments.
CDK inhibition in breast cancer
N Johnson et al
348
British Journal of Cancer (2010) 102(2), 342–350 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
ssmall-molecule inhibitors. The anti-estrogen-resistant cells were
3–5 times less sensitive to tamoxifen compared with MCF7 cells
and between 1.5 and 2.5 times less sensitive than T47D cells.
However, there was very little difference in the sensitivity of the
cells to NU2058 and NU6102 for both inhibition of cell
proliferation and induction of cell death. Of note, MMU2 and
LCC9 cells were more sensitive to NU6102 compared with their
parental MCF7 cells. The progression to anti-estrogen resistance
selects for further deregulation of cell cycle proteins, such as
p27
Kip1 or pRb (Arteaga, 2004; Varma et al, 2007), resulting in an
increased dependency on CDK activity for survival, and potentially
rendering these cells more sensitive to CDK inhibition.
Investigation of the underlying mechanisms of cell growth arrest
focused on MCF7 cells and its anti-estrogen-resistant derivatives,
MMU2 and LCC9 cells, revealed that, in contrast to tamoxifen, to
which only MCF7 cells responded, NU2058 and NU6102 directly
reduced pRb
pThr821 phosphorylation, E2F transcriptional activity
and cell growth in all the cells. Both compounds had little effect
on cyclin D1, p21
Waf1/Cip1 or p27
Kip1 levels, indicating that the
reduction in pRb phosphorylation and cell proliferation were a
result of directly inhibiting CDK activity. Of note, at 15mM
NU6102, total pRb protein levels were also reduced in all MCF7
cell types. This concentration resulted in cell death by colony
assay; therefore, total pRb was probably reduced as a consequence
of cells beginning to die. Further investigation revealed that the
inhibitors did prevent S-phase re-entry after G0/G1 release,
consistent with CDK2 inhibition, and that in asynchronous cells,
they caused predominantly G2/M arrest, which was more
indicative of dual CDK1 and CDK2 inhibition (Cai et al, 2006).
We had previously observed that NU6102 inhibited CDK1-
dependent nucleolin phosphorylation and CDK2-dependent pRb
phosphorylation with equal efficiency in MCF7 cells (Davies et al,
2002), and other studies show that 8mM NU6102 inhibited CDK1-
dependent phosphorylation in prostate cancer cells (Chen et al,
2006). We therefore investigated the effect of NU2058 and NU6102
on CDK1 and CDK2 kinase activity in intact cells. We showed that
neither inhibitor was selective for CDK2 versus CDK1 inside cells,
with both enzymes being inhibited by 50%, by about 60mM
NU2058 and 10mM NU6102. Furthermore, in contrast to data
from enzymatic assays, higher concentrations of NU2058, and in
particular NU6102, were required to inhibit cellular CDK1 and
CDK2. Similar discrepancies between the concentrations required
for enzyme inhibition in cell-free and whole cell assays have been
shown for a range of CDK inhibitors (Pevarello et al, 2005).
Importantly, the concentrations of NU2058 and NU6102 required
to inhibit cell proliferation by 50% were broadly similar to the
concentrations required to inhibit CDK1 and CDK2 in intact cells.
These compounds did not induce p53 accumulation or reduce
RNA polymerase II phosphorylation at the concentrations tested,
indicating that growth inhibition was not due to inhibition of
transcriptional CDKs but was a result of direct inhibition of only
CDK2 and CDK1. Furthermore, there was no increase in cell death
when CDK1 and CDK2 depleted cells were treated with NU2058 or
NU6102. These data provide strong evidence that the affects of
NU2058 and NU6102 on breast cancer cell survival were mediated
through inhibition of only CDK2 and CDK1. In summary, we
have validated CDK2 and CDK1 as therapeutic targets in anti-
estrogen-sensitive and resistant breast cancer cells by showing G1
and G2/M accumulation after CDK2, CDK1 or combined CDK
knockdown, respectively. In addition, we have shown that the dual
CDK1 and CDK2 inhibitors, NU2058 and NU6102, similarly induce
cell cycle arrest and death. Importantly, these compounds inhibit
the proliferation of breast cancer cell lines independent of their
genetic backgrounds or sensitivity to anti-estrogens. These data
provide the ‘proof of principle’ evidence that small-molecule
CDK2/1 inhibitors could be a useful alternative treatment for
breast cancer patients with endocrine-resistant disease.
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